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Abstract
Background: Multiple myeloma is an incurable complex disease characterized by clonal proliferation of malignant
plasma cells in a hypoxic bone marrow environment. Hypoxia-dependent erythropoietin (EPO)-receptor (EPOR)
signaling is central in various cancers, but the relevance of EPOR signaling in multiple myeloma cells has not yet
been thoroughly investigated.
Methods: Myeloma cell lines and malignant plasma cells isolated from bone marrow of myeloma patients were
used in this study. Transcript levels were analysed by quantitative PCR and cell surface levels of EPOR in primary
cells by flow cytometry. Knockdown of EPOR by short interfering RNA was used to show specific EPOR signaling in
the myeloma cell line INA-6. Flow cytometry was used to assess viability in primary cells treated with EPO in the
presence and absence of neutralizing anti-EPOR antibodies. Gene expression data for total therapy 2 (TT2), total
therapy 3A (TT3A) trials and APEX 039 and 040 were retrieved from NIH GEO omnibus and EBI ArrayExpress.
Results: We show that the EPOR is expressed in myeloma cell lines and in primary myeloma cells both at the
mRNA and protein level. Exposure to recombinant human EPO (rhEPO) reduced viability of INA-6 myeloma cell line
and of primary myeloma cells. This effect could be partially reversed by neutralizing antibodies against EPOR. In
INA-6 cells and primary myeloma cells, janus kinase 2 (JAK-2) and extracellular signal regulated kinase 1 and 2
(ERK-1/2) were phosphorylated by rhEPO treatment. Knockdown of EPOR expression in INA-6 cells reduced
rhEPO-induced phospo-JAK-2 and phospho-ERK-1/2. Co-cultures of primary myeloma cells with bone marrow-derived
stroma cells did not protect the myeloma cells from rhEPO-induced cell death. In four different clinical trials, survival data
linked to gene expression analysis indicated that high levels of EPOR mRNA were associated with better survival.
Conclusions: Our results demonstrate for the first time active EPOR signaling in malignant plasma cells. EPO-mediated
EPOR signaling reduced the viability of myeloma cell lines and of malignant primary plasma cells in vitro. Our results
encourage further studies to investigate the importance of EPO/EPOR in multiple myeloma progression and treatment.
Trial registration: [Trial registration number for Total Therapy (TT) 2: NCT00083551 and TT3: NCT00081939].
Keywords: Multiple myeloma, CD138+ cells, Erythropoietin, Erythropoietin-receptor, JAK-2, ERK-1/2, Bone marrow stroma
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polymer chain reaction; TT2/3, Total therapy 2/3
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Background
Multiple myeloma is a malignancy of plasma cells in the
bone marrow. Interaction between the malignant plasma
cells and stromal cells in the bone marrow microenvir-
onment is assumed to support growth and survival of
these cancer cells. This process is characterized by in-
creased microvessel density induced by production of
pro-angiogenic molecules and suppression of angiogenic
inhibitors, a phenomenon called an ‘angiogenic switch’
[1]. Erythropoietin/erythropoietin-receptor (EPO/EPOR)
signaling is the main regulator of proliferation in the
erythroid lineage [2]. However, it recently became appar-
ent that the EPOR also is expressed in several non-
haematopoietic tissues including the central nervous
system, retina, heart, vascular endothelium, kidney, lung,
liver and gastrointestinal and reproductive tracts where
it plays a role in the protection from apoptosis and in-
flammation induced by hypoxia, toxicity or injury [3–5].
The EPO/EPOR interaction initiates a signaling cascade
that activates and recruits a variety of Src homology-2
(SH2) domain-containing proteins that initiate various
downstream signaling pathways such as ERK-1/2 and
JAK-2 [6]. These signaling pathways control cell prolifer-
ation, differentiation and/or death, dependent on the cell
type and context of stimulation. The majority of mye-
loma patients are anaemic and administration of rhEPO
to anaemic patients with advanced myeloma is associ-
ated with prolonged survival [7] and improved immuno-
logical functions [8]. Expression of EPOR mRNA in
plasma cells from myeloma patients has been shown
previously [9], and it was recently shown that primary
myeloma cells expressed EPOR on the surface [10].
However, these studies did not address whether the
EPOR was active in EPO signaling or whether it could
affect primary myeloma growth or viability in vitro. The
role of EPO/EPOR is still unclear in the pathogenesis of
multiple myeloma. We show here that EPO/EPOR sig-
naling is functional in both primary myeloma cells and
cell lines and that recombinant human EPO exhibits a
negative effect on myeloma cell viability in vitro.
Results
EPOR mRNA expression in myeloma cell lines and primary
myeloma cells
The relative levels of EPOR mRNA in purified CD138+
cells from 36 myeloma patients and in seven human
myeloma cell lines (HMCLs) were quantified with qPCR.
Both the patient samples and the HMCLs showed EPOR
expression although to variable extent (Fig. 1a). In order
to investigate whether there was an autocrine EPO/
EPOR signaling in myeloma cells, we measured expres-
sion of EPO mRNA in 20 of the samples. All samples
tested were found negative for EPO mRNA (data not
shown), suggesting that plasma cells do not normally
express significant amounts of EPO and that EPO signal-
ing in myeloma may occur through a paracrine or endo-
crine mechanism.
To examine whether EPO mRNA expression was a
specific trait of malignant plasma cells, we used publicly
available data sets to compare expression in plasma cells
from healthy people and from patients with various
stages of plasma cell neoplasms. We downloaded and
analysed data from the IA7 release of the CoMMpass
data (https://research.themmrf.org), containing expres-
sion data from 484 multiple myeloma patients, and we
found that EPO was not expressed in any of the mye-
loma patients (fragments per kilobase of exon per mil-
lion fragments mapped (FPKM) mean 0.02;(Min:0;
Max:0.73)). Similar to what we had observed, EPOR was
expressed in many of the patients samples, although the
expression levels varied between patients (FPKM mean
5.73;(Min:0.42; Max74.7)). In addition, data from the
Oncomine database revealed a 2-fold increase in expres-
sion of EPOR mRNA expression comparing normal
plasma cells with monoclonal gammopathy of undeter-
mined significance (MGUS) in one study [11], as well as
1.8-fold increase from normal plasma cells to smoulder-
ing myeloma in another study [12].
Presence of EPOR on the cell surface of myeloma cell
lines and primary myeloma cells
Cell surface expression of EPOR on six myeloma cell
lines was estimated by flow cytometry. IH-1, INA-6 and
ANBL-6 expressed the highest levels of EPOR (Fig. 1b),
whereas OH-2 and KJON were negative for EPOR. In
isolated primary myeloma cells, the majority (5/6) of
samples tested expressed EPOR on their surface with ex-
pression ranging from ‘low’ (MM-38) through ‘inter-
mediate’ (MM-40) to ‘high’ expression (MM-39, MM-41
and MM-42) (Fig. 1c).
Recombinant human EPO reduces the viability of primary
myeloma cells and is antagonized by anti-EPOR anti-
bodies in vitro
To assess potential effects of EPOR signaling in mye-
loma cells, three primary myeloma cell samples were in-
cubated with or without rhEPO for 48 h before cell
viability and proliferation were measured using
annexinV-FITC/PI and CellTiter Glo assays, respectively.
Decreased viability and proliferation were observed with
increasing concentrations of rhEPO (Fig. 2a, b), suggest-
ing an inhibitory role of EPO on myeloma cells. In order
to exclude the possibility of a rhEPO-independent cause
for this observation, four additional primary myeloma
cell samples were treated with rhEPO in the absence or
presence of EPOR blocking antibodies. Antibody pre-
treatment to a large extent prevented rhEPO-induced
cell death (Fig. 2c). This supports that the rhEPO is










Fig. 1 The EPOR is expressed both at mRNA and protein levels in primary myeloma cells and cell lines. a Quantitative real-time PCR for EPOR in
36 patient samples (black) and seven HMCLs (gray). Relative quantification (RQ) was calculated using the ΔΔCt method with GAPDH as housekeeping gene.
CAG HMCL was set to 1. Error bars indicate standard deviation of triplicates for each sample. b, c Flow cytometry was used to detect surface EPOR levels in
myeloma cell lines and in primary myeloma samples. The data are Arcsinh transformed showing the Archsinh value of medians, and negative OH-2 is used
in the first row for comparison for the cell lines
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causing the cell death via the EPOR and not due to off-
target effects.
Since bone marrow stroma cells has been shown to
protect plasma cells against stress or pro-apoptotic
agents in vitro, the effect of rhEPO on primary mye-
loma cells were analysed during co-culture with stro-
mal cells. No protective effect in the presence of bone
marrow-derived stromal cells was observed (Fig. 2d).
Taken together, our results suggest that rhEPO reduces
the viability of primary myeloma cells in a specific
EPOR-dependent manner that cannot be prevented by
stromal cells.
EPO/EPOR signaling in myeloma cells
To examine whether myeloma cells were able to signal
via the EPOR, INA-6 cells were incubated with 10 U/ml
rhEPO for 5 min and the levels of phosphorylated (p)-
ERK-1/2 and p-JAK-2 were analysed by immunoblotting.
Increases in phosphorylation of ERK-1/2 and JAK-2 were
observed, suggesting that the EPO/EPOR signaling com-
plex is functional in myeloma cells. Since ERK-1/2 and
JAK-2 also can be activated by upstream signaling mole-
cules other than the EPOR, the experiments were also
performed after knockdown of the EPOR using siRNA.
The levels of p-ERK-1/2 and p-JAK-2 after knockdown
were reduced compared to the control-transfected cells
exposed to rhEPO (Fig. 3a). The efficacy of the siRNA-
mediated EPOR knockdown was examined by immuno-
blotting (Fig. 3b). We therefore conclude that INA-6 has
the potential of functional and specific EPO/EPOR sig-
naling. Examination of primary myeloma cells for their
putative active EPO/EPOR signaling revealed that all
samples (MM-51-MM-54) exhibited activation of both
ERK-1/2 and JAK-2 after 5 min treatment with 10 U/ml
rhEPO (Fig. 3c). Together, these results suggest that
EPO/EPOR signaling may operate in myeloma cells.
Higher levels of EPOR mRNA in malignant plasma cells
are associated with prolonged patient survival
We further asked whether plasma cell expression levels
of EPOR was associated with clinical outcomes of mye-
loma patients. Kaplan-Meier analyses revealed significant
differences in overall survival between ROC-high EPOR-
expresser’s (n = 21) and the remainder of the patients
(N = 257). High levels of EPOR favourably affected the out-
come (Fig. 4). For newly diagnosed myeloma patients in the
Fig. 2 RhEPO-dependent reduction in cell proliferation and viability is counteracted by α-EPOR antibodies but not by stromal cells. Primary myeloma cells
from three patients were treated with rhEPO as indicated and viability and proliferation were analysed. a Viability was measured by annexinV-FITC and PI
staining with flow cytometry after 48 h treatment. Error bars represent variations of duplicates. b Proliferation was measured by cell ATP-release (CellTiterGlo
assay) after 48 h treatment. Error bars represent variations within triplicates. Untreated sample is set to 1 for comparison. c Four primary
myeloma cell samples (MM-44, MM-46, MM-47 and MM-48) were treated with 1 or 2.5 U/ml rhEpo in the presence or absence of neutralizing antibodies
against EPOR as indicated. Error bars represents the variations of means of duplicates of the means of four patient samples. d Four primary
myeloma samples (MM-44, MM-49, MM-50 and MM-51) were cultured with bone marrow stroma cells and 1 U/ml rhEPO. The bone marrow
stroma cells did not protect the primary myeloma cells against the effect of 1 U/ml rhEPO. Error bars represents the variations of means of duplicates of
means of four patient samples
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TT2 (n = 278) and TT3A (n = 245) trials, ROC-high EPOR
expression levels were significantly associated with longer
overall survival (P = 0.004, hazard ratio = 0.17; P = 0.011,
hazard ratio = 0.12, respectively) (Fig. 4a, b). Similarly, for
relapse myeloma patients with one to three prior therapies
in the APEX phase 3 039 (n = 156) and 040 (n = 57) trials,
higher expression levels of EPOR at relapse were signifi-
cantly associated with better overall survival (P < 0. 0001,
hazard ratio = 0. 33; P < 0. 0001, hazard ratio = 0.19, re-
spectively) (Fig. 4c, d). The GEP data were collected at
baseline prior to treatment.
Discussion
Here, we demonstrate that the EPOR is expressed on
the cell surface of myeloma cell lines and on primary
myeloma cells, and show for the first time active EPO/
EPOR signaling in malignant plasma cells. Activation of
EPOR signaling had a negative impact on the viability of
myeloma cell lines and of malignant primary plasma
cells in vitro. The effect on viability was EPO/EPOR-spe-
cific since it could be partly reversed by neutralizing
antibodies against EPOR. Treatment of myeloma cells
with EPO was followed by JAK-2 and ERK-1/2 phos-
phorylation while knockdown of EPOR expression in the
myeloma cell line INA-6 reduced JAK-2 and ERK-1/2
phosphorylation, again demonstrating the specificity of
active EPO/EPOR signaling in myeloma cells. Co-
cultures of primary myeloma cells with bone marrow-
derived stroma cells did not protect the myeloma cells
from EPO-induced death, while the stroma cells were
unaffected. Together, our results suggest that EPO re-
duces the viability of primary myeloma cells in an
EPOR-dependent manner and that the cells cannot be
rescued by stroma cells. The level of EPOR mRNA in all
primary samples as well as cell lines shows a variable
level as measured by PCR. In the cell lines, like OH-2,
EPOR was detected on mRNA levels but not on protein
levels. This is most probably due to posttranscriptional
regulatory mechanisms, causing EPOR expression levels
below detection limits by flow cytometry.
In four different clinical trials, survival data linked to
gene expression analysis indicated that higher level of
EPOR mRNA was associated with better survival. Based
on the survival studies, it is therefore intriguing to
speculate whether active EPO/EPOR signaling may be
favourable for the survival of myeloma patients. In
agreement with this hypothesis, it is reported that ther-
apy with rhEPO leads to longer overall survival in pa-
tients with multiple myeloma [13]. The use of EPOR-
expression as a predictive biomarker to longer survival
should be further explored. One could then get indica-
tions whether supportive treatment with rhEPO is safe
with respect to bone density and whether it could be a
potential to prolong survival in the patients with higher
levels of EPOR expression. We believe, however, that it
would be surprising if EPOR-expression can be a pre-
dictive biomarker on its own (reviewed in [14]).
A central concern, however, in the use of EPO to
treat anaemia in cancer patients is whether tumour
cells express EPOR and therefore could be stimulated
to tumour growth. Also, concern has been raised
whether endothelial cells that express EPOR could be
activated by rhEPO exposure to induce angiogenesis
and thereby indirectly promote tumour growth [15].
The use of rhEPO has therefore been tempered by ad-
verse effects on cancer survival in recent clinical trials
(reviewed in [16]).
It has been a concern that EPO, through its pro-
proliferative effect in pre-erythrocytes, might enhance
myeloma cell growth. Our data points in the opposite
direction, especially for patients with high EPOR expres-
sion, favouring the use of EPO to treat anaemic patients
with rhEPO. In another relevant study, EPO was used
together with granulocyte colony stimulation factor (G-
CSF) to see if eltrombopag (small non-peptide molecule
that stimulates megakaryopoises in bone marrow) af-
fected the proliferative capacity of human myeloma cells.
These results showed no effect of EPO and G-CSF to-


















Fig. 3 EPOR signaling in myeloma cells. a Knockdown of EPOR in
INA-6 reduces p-ERK-1/2 and p-JAK-2 after rhEPO treatment (10 U/ml,
5 min). b Immunoblotting shows specific knockdown of EPOR in INA-6
cells using siRNA directed against EPOR mRNA. c Immunoblotting of four
different primary myeloma cells after rhEPO treatment (10 U/ml, 5 min)
shows an increase in both p-ERK1/2 and p-JAK-2 in the patient samples
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in another. They also show that drug combination did
not reverse the apoptotic effect of lenalidomide or borte-
zomib, strengthening the fact that neither drug has pro-
proliferative or anti-apoptotic effects [17].
In a newly published paper, lenalidomide was shown
to increase EPOR levels by inhibiting the E3 ubiquitin
ligase RNF41 in cells from the myeloid lineage involved
in myelodysplastic syndrome. It is not known if this is
also true for the plasma cells, but may open for a com-
binatorial treatment strategy between lenalidomide and
EPO [18].
In another relevant study, it was found that mice
(5T33MM murine myeloma model) treated with EPO
showed accelerating bone resorption as measured by μ-
CT, and was suggested to be caused by activation of
bone marrow-derived macrophages [19]. These data
were obtained in a mouse model and possible effects on
bone density should be analysed in humans after EPO
treatment. It would also be interesting to follow up and
compare bone density in patients treated with both EPO
and lenalidomide as a follow up from the Basiorka-
studies [18]. A series of new upcoming treatments for
myeloma is proposed and/or in clinical trials [20]. It
would be interesting to analyse the effect of EPO as
combinatory drug in at least some of these suggested
treatment regimes.
Another intriguing observation from our study is the
EPO-dependent activation of ERK, a typical hallmark of
anti-apoptosis, which concurred with reduced viability.
Most often, ERK and AKT pathways offer survival sig-
nals that protect cells from apoptosis [21]; however, in-
creasing evidence reveals that ERK activation may
contribute to apoptosis in certain cell types. For ex-
ample, inhibition of ERK (by U0126) was renal protect-
ive in cisplatin-induced nephrotoxicity in mice [22],
while in renal epithelial cells, cisplatin induces ERK acti-
vation and inhibition of ERK blocked apoptosis [23–25].
Furthermore, ERK activation contributes to apoptosis in
OK cells following H2O2 treatment [26], while in a re-
cent study, ERK activation was crucial in mediating
triptolide-induced apoptosis [27]. Also in cultures of hu-
man neuroblastoma cells (h-NMB), EPO inhibits growth,
while it stimulates differentiation [28]. Consequently,
our observation that EPO-mediated ERK activation in
Fig. 4 Prognostic relevance of EPOR expression from four independent patient cohorts. With the use of ROC optimal cutoff derived from each
trial, overall survival analysis was performed on EPOR expression in the a TT2, b TT3A, c APEX trial 039 and d APEX trial 040 datasets. Low
expression levels of EPOR adversely affect outcomes in all patient cohorts
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myeloma cells is associated with reduced viability and
adds to a growing list of instances of ERK activation
concomitant with cell death. The JAK-2 activation and
further trigging of apoptosis in the myeloma cells might
become an issue if the myeloma patient is simultan-
eously treated with a JAK-inhibitor (e.g. AT9283 or rux-
olitinib), and this should be investigated before treating
patients in JAK-inhibitor clinical trials with supportive
EPO therapy [29].
Our attempts to map possible EPO-dependent activa-
tion of p38 and JNK signaling pathways failed and map-
ping of these pathways is still inconclusive.
Together, this study shows that primary myeloma cells
display active EPO/EPOR signaling and that rhEPO may
induce myeloma cell death in vitro, both in monoculture
and in co-culture of primary cells with myeloma-derived
bone marrow stroma cells. Four independent survival
studies establish a link between elevated EPOR-
expression in myeloma cells and beneficial patient out-
come and suggest that EPOR expression can be a novel
prognostic marker for newly diagnosed myeloma.
Conclusions
These results demonstrate for the first time that EPO/
EPOR signaling is active in malignant plasma cells. Re-
duced viability and proliferation was observed both in
cell lines and in primary myeloma cells upon treatment
with rhEPO in vitro. The concomitant observation that
higher EPOR expression is associated with survival in
four different therapy strategies should encourage fur-
ther studies to reveal the relevance of EPO/EPOR signal-
ing in multiple myeloma progression.
Methods
Cell lines and primary multiple myeloma cells
The myeloma cell lines and CD138+ primary plasma
cells from myeloma patients were grown and maintained
as described [30]. Isolation of CD138+ cells for experi-
ment demanding fresh viable cells and co-culture of
CD138+ cells and bone marrow stromal cells were done
as previously reported [30]. The project was approved by
the Regional Ethics Committee (REK 2011/2029) and all
patients has given informed consent.
Transfection
For transient gene expression studies, INA-6 cells were
transfected following the instructions for the Nucleofec-
tor device (Amaxa Biosystems, Cologne, Germany) using
2,5 μg CD4 plasmid, Hs_ EpoR_5 Flexitube siRNA,
Hs_EpoR_6 siRNA (SI02780351, SI02780400, Qiagen,
MD, USA) or control siRNA (Qiagen). The INA-6 cell
line was used in the knockdown studies since it is trans-
fectable and because it had a relatively high level of
EPOR expression. After 24 h, transfected cells were
isolated using dynaBeads anti-CD4 separation (Dynal,
Oslo, Norway). Cells were treated with rhEPO (10 U/ml)
(sigma E5627, 100,000 U/mg protein) 48 h after
transfection.
Real-time RT-PCR
RNA was isolated and cDNA was made as previously de-
scribed [12] from primary patient samples and cell lines.
TaqMan probes were used to detect the EPOR and EPO
expression (Hs00959432_g1 and Hs01071096_g1, re-
spectively, gene expression assays, Applied Biosystems,
Foster City, CA). The comparative Ct-method was used
for quantification with GAPDH (HS99999905_m1) as
housekeeping gene on the StepOnePlus Real-Time PCR
system (Applied Biosystems).
Detection of EPOR on the surface of myeloma cells
EPOR on the surface of myeloma cells was stained with
allophycocyanin (APC)-labelled anti-EPO receptor anti-
body [clone 12 K90] from Life Span Biosciences Inc (LS-
C182845), 20 μl/ml for 30 min on ice after 20 min prein-
cubation with human Fc receptor binding inhibitor
(eBioscience, 50 μl/ml). Isotype control mouse IgG1
APC MG105 (Invitrogen) was used. All incubations were
performed in PBS/1 % BSA. Flow cytometry was per-
formed using LSR II (Becton Dickinson) with FACS Diva
software (Becton Dickinson), and analysed with Cyto-
bank [31]. Gates were set on live cells with forward and
side scatter and duplets were excluded.
Viability and proliferation assay
AnnexinV-FITC/PI staining (Abcam, ab14085) and analysis
by flow cytometry was used to assess viability in the pri-
mary cells incubated with rhEPO in the presence or ab-
sence of anti-EPOR antibodies (Santa Cruz: sc101444,
clone MM0031-6G7). The anti-EPOR was preincubated for
30 min together with the primary cells before rhEPO was
added. Cell proliferation assay was performed after 48 h in-
cubation with rhEPO using CellTiter-Glo® Luminescent
Cell Viability Assay (Promega, Madison, Wisconsin)
according to the manufacturer’s instructions.
Western blot analysis
INA-6 was washed 4× in Hanks’ balanced salt solution,
incubated for 4 h in 1 % BSA in RPMI before treatment
with 10 U/ml rhEPO for 5 min. Primary samples were
seeded in 1 % BSA in RPMI and starved for 4 h before
treatment with rhEPO, 10 U/ml, 5 min. Lysates of INA-
6 and primary cells were made as previously described
[32]. Samples were subjected to electrophoreses and
transferred to membranes by blotting. Membranes were
then blocked with non-fat dried milk (5 %) in Tris-
buffered saline supplemented with Tween-20 (TBS-T)
(0.1 %) and incubated with antibody against p-ERK-1/2
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(rabbit polyclonal IgG, Cell Signalling, 1:1000 and EPOR
(sc101444, Santa Cruz, 1:200). For detecting p-JAK-2,
membranes were blocked in 5 % BSA in TBS-T and
incubated with antibody against p-JAK-2 (rabbit IgG anti
p-JAK-2, Cell Signalling, 1:200). All antibodies were incu-
bated up to 72 h at 4 °C. GAPDH (Abcam, Cambridge, UK,
1:50,000) was used as loading control. Antibody binding
was visualized with Odyssey Licor detecting system using
L680 anti-rabbit or L800 anti-mouse (1:20 000 in TBS-T).
ScanR microscope-based screening and cell viability assay
Cell viability experiments of co-cultures were performed
using a ScanR-automated fluorescence microscope
(Olympus, Hamburg, Germany). Acquired images were
analysed using the ScanR Image Analysis software.
Image acquisition and analysis of myeloma cell viability
was performed as described [30]].
Gene expression profiling and statistical analysis
Gene expression data for newly diagnosed myeloma
patients without prior therapy in the total therapy 2 (TT2)
and total therapy 3A (TT3A) trials were retrieved from
NIH GEO omnibus under accession number GSE2658
and EBI ArrayExpress under the accession number E-
TABM-1138. Gene expression data for the relapsed mye-
loma patients with one to three prior therapies in the
APEX phase 3 trial 039 and 040 trials were retrieved from
NIH GEO omnibus under accession number GSE9782.
There are six probe sets designated to EPOR (19p13.2) on
both U133Plus2.0 and U133A microarray platforms.
Among them, probe set 209962_at was consensually se-
lected due to compatibility of two types of Affymetrix
microarrays and oligo-sequence alignment to EPOR locus.
Because the patients enrolled to TT2 and TT3A trials
were treated under different regimens, the receiver-
operating characteristic (ROC) optimal cut point for
EPOR in each clinical trial was identified with the running
log-rank test, respectively, based on overall survival of the
cohorts at the time of data collection [33]. Hazard ratios
were calculated by the Cox proportional model. All statis-
tical computations were performed using R (version
2.13.2; available from http://www.r-project.org) and Bio-
conductor (available from http://www.bioconductor.org).
Patients and sample collection of material for gene
expression profiling in clinical trials
The information of Total Therapy (TT) 2 [NCT00083551
[34] and TT3 [NCT00081939 [35] trials were published at
the web site of National Institutes of Health (https://clini
caltrials.gov). The baseline bone marrow aspirates were
harvested from the patients at diagnosis of MM according
to established procedures at the University of Arkansas for
Medical Sciences (UAMS). Bone marrow specimens were
processed to obtain CD138+ plasma cells for gene
expression profiling [11]. The study was approved by the
Institutional Review Board of UAMS, and informed con-
sents were obtained from all study subjects and kept on
record in accordance with the Declaration of Helsinki.
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